Crossmark

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

Crossref DOI link: https://doi.org/10.1038/nbt.4181

Published Online: 2018-07-09

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tang, Li https://orcid.org/0000-0002-6393-982X
Zheng, Yiran

Melo, Mariane Bandeira

Mabardi, Llian

Castaño, Ana P

Xie, Yu-Qing

Li, Na

Kudchodkar, Sagar B https://orcid.org/0000-0003-1754-6803
Wong, Hing C

Jeng, Emily K

Maus, Marcela V https://orcid.org/0000-0002-7578-0393
Irvine, Darrell J
License Information

Text and Data Mining valid from 2018-07-09
More Information

Article History

Received: 4 June 2016

Accepted: 7 June 2018

First Online: 9 July 2018

Competing interests

: D.J.I., L.T., and Y.Z. are inventors on licensed patents related to the technology described in this manuscript. D.J.I. is a co-founder of Torque Therapeutics, which licensed patents related to this technology.